A Study of Repotrectinib in Combination With Other Anticancer Therapies for the Treatment of Subjects With KRAS-Mutant Solid Tumors
Part of paid clinical trials in California City, California.
- Sponsor
- Turning Point Therapeutics, Inc.
- Study ID
- NCT05071183
- Phase
- PHASE1/PHASE2
- Status
- Terminated
Conditions
- Advanced Solid Tumor
- KRAS Mutation-Related Tumors
- Metastatic Solid Tumor
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - N/A
- Healthy Volunteers
- Not accepted
Interventions
- TPX-0005 — DRUGOral TPX-0005 capsules
- Trametinib — DRUGOral trametinib tablets
Study Details
A Phase 1b/2 Study of Repotrectinib in Combination with Other Anticancer Therapies for the Treatment of Subjects with KRAS-Mutant Advanced Solid Tumors (TRIDENT-2)
Key Dates
- Start date
- Sep 23, 2021
- Status verified
- Mar 2024
- Primary completion
- Mar 1, 2023
- Completion
- Mar 1, 2023
Study Design
- Enrollment
- 9 participants (actual)
- Allocation
- NA
- Intervention model
- SINGLE_GROUP
- Primary purpose
- TREATMENT
Arms
- Experimental: TPX-0005 + TrametinibTPX-0005 + Trametinib Dose Escalation and Dose Expansion Dose escalation: KRAS G12D mutant advanced solid tumors. Dose expansion: KRAS G12D locally advanced or metastatic NSCLC
Primary Outcome Measure
Number of Participants With Dose Limiting Toxicities [ Time Frame: From initial dose to end of first cycle of treatment, approximately 28 days ]
Locations (6)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| Local Institution - 2101 | California City | California | 90033 | - |
| Local Institution - 2109 | California City | California | 92663 | - |
| Local Institution - 2106 | Denver | Colorado | 80218 | - |
| Local Institution - 2108 | Nashville | Tennessee | 37203 | - |
| Local Institution - 2107 | Houston | Texas | 77030 | - |
| Local Institution - 2102 | Virginia Beach | Virginia | 22031 | - |
Find similar trials in California City, CA
Related Studies
- A Study of Tulmimetostat DZR123 (CPI-0209) in Patients With Advanced Solid Tumors and LymphomasPHASE1/PHASE2 · Recruiting · Novartis Pharmaceuticals · Atlanta, Georgia
- Study of Ifinatamab Deruxtecan (DS-7300a, I-DXd) in Participants With Advanced Solid Malignant TumorsPHASE1/PHASE2 · Recruiting · Daiichi Sankyo · Los Angeles, California
- Evaluate the Safety and Clinical Activity of HH2853PHASE1/PHASE2 · Recruiting · Haihe Biopharma Co., Ltd. · Phoenix, Arizona
- The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)PHASE1/PHASE2 · Recruiting · PMV Pharmaceuticals, Inc · Irvine, California